Pathstone Holdings
MIRM icon

Pathstone Holdings’s Mirum Pharmaceuticals MIRM Stock Holding History

Pathstone Holdings’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.84M Sell
24,270
-1,305
-5% -$131K 0.01% 918
2026
Q1 		$2.36M Buy
25,575
+3,899
+18% +$367K 0.01% 939
2025
Q4 		$1.71M Buy
+21,676
New +$1.56M 0.01% 1117

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings's MIRM Position: Q2 2026 in Review

Pathstone Holdings reduced its Mirum Pharmaceuticals (MIRM) stake by 5.1% in Q2 2026, selling an estimated $131K and leaving 24,270 shares worth $2.84M. The position accounts for 0.01% of the portfolio, ranked #918.

Pathstone Holdings first reported a position in MIRM in Q4 2025 and has held it in 3 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Pathstone Holdings held 24,270 shares of Mirum Pharmaceuticals worth $2.84M as of Q2 2026.
  • Pathstone Holdings sold 1,305 Mirum Pharmaceuticals shares in Q2 2026, an estimated $131K.
  • Mirum Pharmaceuticals made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #918 holding.
  • Pathstone Holdings first reported a position in Mirum Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.